Contraception Guidance Sample Clauses

Contraception Guidance. Women of childbearing potential must agree to use (or have their male partner use) a highly effective contraception method, unless any of the following apply: • Has reached natural menopause, defined as at least 12 months of spontaneous amenorrhea without an alternative medical cause; • Is permanently sterile, following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy. Highly effective methods of contraception include the following: • Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation, which may be oral, intravaginal or transdermal • Progestogen-only hormonal contraception associated with inhibition of ovulation, which may be oral, injectable, or implantable intrauterine device (IUD) • Intrauterine hormone-releasing system (IUS) • Bilateral tubal occlusion (including ligation and blockage methods such as Essure™ at least 6 months prior to the initial Screening Visit [subjects with Essure must have prior confirmation of tubal occlusion by hysterosalpingogram])‌ • Sexual partner(s) who was documented to be vasectomized at least 6 months prior to the Screening Visit • Sexual abstinence from heterosexual intercourse Subjects will be provided with information on acceptable methods of contraception as part of the informed consent process and will confirm when they sign an ICF that they understand the requirements for avoidance of pregnancy during the course of the study. These methods of contraception are only effective when used consistently, correctly, and in accordance with the product label. The Investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception.
Sample 1
AutoNDA by SimpleDocs
Contraception Guidance. There is no known drug interaction between RIST4721 and hormonal contraception. Male Subjects: Male subjects are eligible to participate if they agree to the following from informed consent through 5 days after the last dose of study treatment: • Be abstinent and agree to remain abstinent OR • Must agree to use contraception/barrier (a male condom) and spermicide Female Subjects: • A female subject is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: − Is not a WOCBP OR − Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), preferably with low user dependency (see table below), from consent through 5 days after the last dose of study treatment, and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study treatment. − A WOCBP must have negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) at screening and a negative urine pregnancy test before first administration of study treatment. On-treatment urine pregnancy tests will be done routinely as specified in the SoA. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required and results must be negative. Contraceptive use by men or women should be consistent with local regulations regarding the use of contraceptive methods for those participating in clinical studies. Highly Effective Methodsa That Have Low User Dependency • Implantable progestogen-only hormone contraception associated with inhibition of ovulationb • Intrauterine device (IUD) (hormonal and non-hormonal) • Surgical sterilization • Bilateral tubal occlusion or ligation • Vasectomized partner (Vasectomized partner is a highly effective contraceptive method provided that the partner is the sole sexual partner of the WOCBP. If not, an additional highly effective method of contraception should be used. Spermatogenesis cycle is approximately 90 days.) Highly Effective Methodsa That Are User-Dependent • Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation − oral − intravaginal − transdermal − injectable • Progestogen-only hormone contraception associated with inhibition of ovulationb − oral − injectable • Sexual a...
Sample 1

Related to Contraception Guidance

  • Network Interface Device (NID) 2.7.1 The NID is defined as any means of interconnection of end-user customer premises wiring to BellSouth’s distribution plant, such as a cross-connect device used for that purpose. The NID is a single-line termination device or that portion of a multiple-line termination device required to terminate a single line or circuit at the premises. The NID features two independent xxxxxxxx or divisions that separate the service provider’s network from the end user’s customer-premises wiring. Each chamber or division contains the appropriate connection points or posts to which the service provider and the end user each make their connections. The NID provides a protective ground connection and is capable of terminating cables such as twisted pair cable.

  • Protocols Each party hereby agrees that the inclusion of additional protocols may be required to make this Agreement specific. All such protocols shall be negotiated, determined and agreed upon by both parties hereto.

  • Interoperability To the extent required by applicable law, Cisco shall provide You with the interface information needed to achieve interoperability between the Software and another independently created program. Cisco will provide this interface information at Your written request after you pay Cisco’s licensing fees (if any). You will keep this information in strict confidence and strictly follow any applicable terms and conditions upon which Cisco makes such information available.

  • How to File an Appeal of a Prescription Drug Denial For denials of a prescription drug claim based on our determination that the service was not medically necessary or appropriate, or that the service was experimental or investigational, you may request an appeal without first submitting a request for reconsideration. You or your physician may file a written or verbal prescription drug appeal with our pharmacy benefits manager (PBM). The prescription drug appeal must be submitted to us within one hundred and eighty (180) calendar days of the initial determination letter. You will receive written notification of our determination within thirty (30) calendar days from the receipt of your appeal. How to File an Expedited Appeal Your appeal may require immediate action if a delay in treatment could seriously jeopardize your health or your ability to regain maximum function, or would cause you severe pain. To request an expedited appeal of a denial related to services that have not yet been rendered (a preauthorization review) or for on-going services (a concurrent review), you or your healthcare provider should call: • our Grievance and Appeals Unit; or • our pharmacy benefits manager for a prescription drug appeal. Please see Section 9 for contact information. You will be notified of our decision no later than seventy-two (72) hours after our receipt of the request. You may not request an expedited review of covered healthcare services already received.

  • COVID-19 Protocols Contractor will abide by all applicable COVID-19 protocols set forth in the District’s Reopening and COVID-19 Mitigation Plan and the safety guidelines for COVID-19 prevention established by the California Department of Public Health and the Ventura County Department of Public Health.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Hot Weather Guidelines For the purposes of site based discussions regarding the need to plan and perform work during expected periods of hot weather, the following issues shall be considered in conjunction with proper consideration of Occupational Health and Safety issues.

  • Data Encryption Contractor must encrypt all State data at rest and in transit, in compliance with FIPS Publication 140-2 or applicable law, regulation or rule, whichever is a higher standard. All encryption keys must be unique to State data. Contractor will secure and protect all encryption keys to State data. Encryption keys to State data will only be accessed by Contractor as necessary for performance of this Contract.

  • Prescription Drug Plan Effective July 1, 2011, retail and mail order prescription drug copays for bargaining unit employees shall be as follows: Type of Drug Prescriptions for 1-45 Days (1 copay) Prescriptions for 46-90 Days (2 copays) Generic drug $10 $20 Preferred brand name drug $25 $50 Non-preferred brand name drug $40 $80 Effective July 1, 2011, for each plan year the Prescription Drug annual out-of- pocket copay maximum shall be $1,000 for individual coverage and $1,500 for employee and spouse, employee and child, or employee and family coverage.

Time is Money Join Law Insider Premium to draft better contracts faster.